AI‑driven biologics developer Earendil Labs secured an exclusive license to WuXi XDC’s WuXiTecan‑2 payload‑linker technology and CRDMO services in a deal worth up to $885 million in upfront and milestone payments plus tiered royalties. The agreement gives Earendil access to a linker‑payload platform intended to accelerate next‑generation antibody‑drug conjugates and will see WuXi XDC support manufacturing. Both companies cited the pact as a route to speed ADC development for multiple oncology targets.